Streetbeat News

BMEA

Biomea Fusion, Inc.

Industry

Biotechnology

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Open

7.02

Mkt cap

237M

Volume

907K

High

7.11

P/E Ratio

-1.62

52-wk high

22.74

Low

6.48

Div yield

N/A

52-wk low

3.61

Patterson Companies, Inc. (PDCO) shares fell by 14% after reporting Q2 earnings of $0.50 per share, missing estimates of $0.58 per share, and lowering FY24 adjusted EPS guidance below expectations. The company's sales were $1.65 billion, below the expected $1.70 billion. Other stocks moved in the mid-day session with various companies experiencing significant gains or losses due to various factors such as FDA clearances, earnings reports, acquisition announcements, and public offerings.

Portfolio Pulse from Lisa Levin

November 29, 2023 | 7:02 pm

Health care stocks experienced significant movement in Wednesday's intraday session. Vivos Therapeutics (VVOS) saw a massive increase of 312.8%, while BioVie (BIVI) faced a sharp decline of 61.9%. Other notable gainers include China Pharma Holding (CPHI), Altamira Therapeutics (CYTO), Envoy Medical (COCH), Biomea Fusion (BMEA), and vTv Therapeutics (VTVT). On the losing side, BiomX (PHGE), Eagle Pharmaceuticals (EGRX), Journey Medical (DERM), Biodexa Pharmaceuticals (BDRX), and Patterson Cos (PDCO) saw significant drops, with PDCO specifically reacting to its Q2 earnings report.

Portfolio Pulse from Benzinga Insights

November 29, 2023 | 5:31 pm

Workday, Inc. (NASDAQ:WDAY) shares increased by approximately 9% in pre-market trading following the company's release of third-quarter earnings that exceeded expectations. Workday reported earnings of $1.56 per share, surpassing the estimated $1.41 per share, and revenue of $1.87 billion, which was higher than the forecasted $1.848 billion. The company expects fourth-quarter subscription revenue of $6.598 billion and adjusted operating margins of 23.8%. Piper Sandler maintained an Overweight rating on Workday and increased the price target from $275 to $300. The article also lists other stocks that moved in pre-market trading, with some experiencing significant gains and others facing declines.

Portfolio Pulse from Lisa Levin

November 29, 2023 | 1:11 pm

In Wednesday's pre-market session, several healthcare stocks showed significant movement. Vivos Therapeutics (VVOS) saw a substantial increase of 132.6%, while Avenue Therapeutics (ATXI) and Redhill Biopharma (RDHL) also experienced notable gains. Conversely, Eagle Pharmaceuticals (EGRX) and Heart Test Laboratories (HSCS) were among the stocks that declined. Patterson Cos (PDCO) reported Q2 earnings, which may have influenced its stock decrease.

Portfolio Pulse from Benzinga Insights

November 29, 2023 | 1:07 pm

Biomea Fusion, Inc. (NASDAQ:BMEA) will present new data from its ongoing Phase II study of BMF-219 in patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease. The abstract will discuss the role of menin as a regulator of glycemic control and beta-cell mass, and illustrate the mechanism of action of BMF-219. Topline data of the escalation portion of COVALENT-111 will be announced in December.